Intelligence / B2B SaaS / Acquisitions / Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc.
19 Oct 2026: Completed an acquisition (SEC 8-K) · Medical devices. Recorded in the SEC EDGAR full-text search.
- Filed
- 19 Oct 2026
- Ticker
- VVOS
- Role
- Completed an acquisition
- Sector
- Medical devices
- Sic
- 3841
- Items
- 1.01, 2.01, 3.02, 3.03, 5.03, 7.01, 8.01, 9.01
- Summary
- On the Closing Date, the Company completed the acquisition of (i) 3,057,879 shares of common stock of SOD (the " SOD Shares "), representing at least eleven percent (11%) of SOD's fully diluted capital stock immediately after the Closing (as adjusted, in accordance with Section 1.1 of the Agreement, from the 2,907,338
- Location
- Littleton, CO
- State
- Colorado
- Country
- United States
- SEC CIK
- 1716166
- Reference
- 0001493152-26-047601
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Find the decision makers at Vivos Therapeutics, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
Across AOS Research
Other records for Vivos Therapeutics, Inc. in our registers.
More in Completed an acquisition
Acquisitions
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.